Inclusion Criteria:

          -  Ability to comprehend and willingness to sign an ICF.

          -  Willing and able to conform to and comply with all Protocol requirements.

          -  Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian
             cancer, TNBC, CRPC or bladder cancer that progressed after treatment with available
             therapies (including anti PD-(L)1 therapy (if applicable).

          -  Willingness to undergo pre- and on-treatment tumor biopsy.

          -  Have CD8 T-cell-positive tumors.

          -  Presence of measurable disease according to RECIST v1.1.

          -  ECOG performance status 0 to 1.

          -  Life expectancy > 12 weeks.

          -  Willingness to avoid pregnancy or fathering children based.

          -  Acceptable laboratory parameters

        Exclusion Criteria:

          -  Clinically significant cardiac disease.

          -  Known or active CNS metastases and/or carcinomatous meningitis.

          -  Active or inactive autoimmune disease or syndrome that required systemic treatment in
             the past 2 years or receiving systemic therapy for an autoimmune or inflammatory
             disease..

          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses
             > 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive
             therapy within 7 days before the first dose of study treatment.

          -  Known additional malignancy that is progressing or requires active treatment,or
             history of other malignancy within 2 years of the first dose of study treatment.

          -  Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or
             complications from prior surgical intervention before starting study treatment.

          -  Evidence of interstitial lung disease, history of interstitial lung disease, or
             active, noninfectious pneumonitis.

          -  Immune-related toxicity during prior immune therapy for which permanent
             discontinuation of therapy is recommended, or any immune-related toxicity requiring
             intensive or prolonged immunosuppression to manage.

          -  Any prior chemotherapy, biological therapy, or targeted therapy to treat the
             participant's disease within 5 half-lives or 28 days (whichever is shorter) before the
             first dose of study treatment.

          -  Any prior radiation therapy within 28 days before the first dose of study treatment.

          -  Undergoing treatment with another investigational medication or having been treated
             with an investigational medication within 5 half-lives or 28 days (whichever is
             shorter) before the first dose of study treatment.

          -  Concomitant treatment with strong CYP3A4 inhibitors or inducers.

          -  Receipt of a live vaccine within 30 days of the first dose of study treatment.

          -  Infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week
             of the first dose of study treatment.

          -  Evidence of HBV or HCV infection or risk of reactivation.

          -  Known history of HIV (HIV 1/2 antibodies).

          -  History of organ transplant, including allogeneic stem-cell transplantation.

          -  Known hypersensitivity or severe reaction to any component of study drug(s) or
             formulation components.

          -  Inability to swallow food or any condition of the upper gastrointestinal tract that
             precludes administration of oral medications.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study.

          -  Any condition that would, in the investigator's judgment, interfere with full
             participation in the study,pose a significant risk to the participant; or interfere
             with interpretation of study data